Showing results (61-70 of 115) with videos related to
Sort By:
Pageof 12
The Journal of Dermatology|January 25, 2024
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trialShinichi Imafuku, Yukari Okubo, Yayoi Tada, et al.The Journal of Dermatology|May 10, 2025
Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance StudyMamitaro Ohtsuki, Yukari Okubo, Hidehisa Saeki, et al.Arerugi = [Allergy]|February 22, 2019
[THE ANALYSIS OF ANAPHYLAXIS DIAGNOSED AT DERMATOLOGY OF TOKYO MEDICAL UNIVERSITY HOSPITAL]Risa Jo, Tomonobu Ito, Tomoko Kobayashi, et al.Arerugi = [Allergy]|July 13, 2022
[A CHILD CASE OF DIFFUSE CUTANEOUS MASTOCYTOSIS]Yu Hoshino, Kaoruko Yoshida, Takafumi Numata, et al.The Journal of Dermatology|October 24, 2002
Increased microorganisms DNA levels in peripheral blood monocytes from psoriatic patients using PCR with universal ribosomal RNA primersYukari Okubo, Noriko Oki, Hidemi Takeda, et al.International Journal of Dermatology|January 28, 2020
Characteristics of Japanese patients with pustulotic arthro-osteitis associated with palmoplantar pustulosis: a multicenter studyToshiyuki Yamamoto, Tomoko Hiraiwa, Rie Tobita, et al.The Journal of Dermatology|April 10, 2017
Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trialMamitaro Ohtsuki, Yukari Okubo, Mayumi Komine, et al.Journal of Dermatological Science|March 21, 2022
Nail lesions in palmoplantar pustulosis and pustulotic arthro-osteitis impairs patients' quality of life: Suggesting new assessment tool of PPP nail lesionsKana Masuda-Kuroki, Hiroshi Kawakami, Namiko Abe, et al.Dermatology and Therapy|August 11, 2025
Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 StudyYukari Okubo, Yayoi Tada, Hidetoshi Takahashi, et al.The Journal of Dermatology|July 27, 2025
Questionnaire Survey on the Treatment of Psoriasis Patients Who Achieved Remission With BiologicsKoji Kamiya, Yukari Okubo, Yayoi Tada, et al.Pageof 12